A recent survey on the global wound care market revealed that each year, more than 305 million acute, traumatic, and burn wounds are recorded and treated globally. These figures are more than nine times the total number of people around the world fighting cancer. In a nutshell, the world today is in dire need of innovative wound care technologies and treatments that can aid the increasing number of patients.
“Chronic wounds affect 6.5 million patients in the United States alone,” says Bob Maguire, the President, and CEO of BioLab Sciences. He continues, “We are entering the market with an advanced, tissue biomanufacturing approach that offers a viable, effective solution for skin regeneration and repair. This innovative strategy has shown to accelerate the healing of damaged soft tissue and improve wound-care outcomes.”
Headquartered in Scottsdale, AZ, BioLab Sciences is an innovative, regenerative biotechnology company focused on creating new ways to regenerate soft tissues for optimal performance. Through its products and patents, the company envisions expanding the human body’s ability to regenerate by developing and manufacturing human cell and tissue therapies as an alternative to invasive, painful, and expensive treatment protocols. The firm’s flagship offering—MyOwn Skin— is a revolutionary approach that uses a patient’s own skin to accelerate healing of chronic wounds, burns, diabetic foot ulcers, and other difficult-to-heal wounds. By utilizing a small skin sample, this regenerative approach allows the body to heal itself quickly and is less likely to face infection or rejection. In fact, the painless, non-surgical procedure can produce partial-thickness skin grafts within 5-7 days. This process is done without the need of harvesting skin from other parts of the patient’s body, which can lead to greater pain than the original wound as well as lead to the possibility of infection.
Even though the MyOwn Skin approach is essentially new to the wound care market, a case report published in PRS Global Open has shown that such procedures are both safe and effective. In the report, researchers have highlighted two cases in which these membrane sheets created from a patient’s own cells were used to cover denuded areas in neonates: one with an extravasation injury and the second case with a burn by boiling liquid.
The first case was on a female pre-term newborn, 36 weeks gestation, who required hospitalization in the pediatric intensive care unit for neonatal adaptation. During the hospital stay, she suffered focal ischemia related to intravenous fluid extravasation in the dorsum of the right foot, which led to skin necrosis. The skin sample was collected, and after seven days (corresponding to the 22nd day after birth), surgical debridement was performed, and the lesion was covered with the autologous keratinocyte sheet. After five days, the surgical area was evaluated, finding partial epithelialization. A complete epithelialization was obtained 15 days after the cultured keratinocyte sheet placement. During the process, the patient never demonstrated signs of infection, hypersensitivity reactions, or systemic deterioration. After a follow up visit after one-year, the resulting scar was considered favorable, given its flexibility, no retractions, and without movement limitations of the toes.
The second case was a one-day-old newborn who suffered a superficial and deep second-grade scalding burn in both feet with compromise of the fourth and fifth toes of the right foot. Initially, a conservative management was implemented, consisting of periodical dressing changes to favor debridement. The first surgical debridement was performed at seven days when the skin and blood samples were collected, and the autologous keratinocyte sheet was fabricated. After seven days, coverage of skin defects with cultured keratinocytes was present. The first evaluation was made five days after the placement of the keratinocyte graft, in which partial epithelialization was encountered, accompanied by scarce serous secretion. Two days later (seven days after sheet placement), the surgical area was re-evaluated, finding complete epithelialization. After a follow up, one-year later, the scar was considered favorable, found to be compliant, and without hypertrophy or retractions. “The groundbreaking field of regenerative medicine has come a long way. The dream of regenerating the body for optimal performance is now a reality with MyOwn Skin,” asserts Maguire.
As an extension to its offerings, BioLab’s impressive portfolio of regenerative products includes its amnion-derived fluid products: Fluid Flow and Amino Restore and its amniotic allograft membrane product: Membrane Graft, an amnion membrane allograft composed of a connective tissue matrix that regenerates soft tissue while inhibiting inflammation and scarring. The company also offers a comprehensive wound care kit that provides physicians with the necessary tools to help patients recover quickly from diabetic ulcers, burns and other traumatic external wounds , as well as its Amnio Breathe Nebulizer bundled package designed to deliver a topical treatment directly onto a patient’s respiratory system.
Since its inception, BioLab Sciences has stayed committed to the development of innovative, regenerative medical technologies to improve the quality of life for people. With a steadily growing network of distributors who have strong relationships with medical practices, physicians, and hospitals, the company envisions researching better ways to address orthopedic injuries, wound care, pain management, aesthetic medicine, respiratory ailments, cardiovascular indications, ophthalmic issues, and more, in the days to come.